Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 809 results for "iibs"

Markets await revamped IIBs from Reserve Bank

The much-publicised Inflation-Indexed Bonds (IIBs) failed to attract investor interest, either retail or institutional, in the last financial year. The Reserve Bank of India (RBI) is now planning to re-launch this product in a restructured form. ... The Hindu, 5 days ago

76 images for iibs

CIO-Asia, 1 week ago
Irish Examiner, 6 days ago
EuroInvestor, 1 week ago
Digital News Asia, 3 weeks ago
Shutterbug, 2 weeks ago
Shutterbug, 2 weeks ago
Shutterbug, 2 weeks ago
Raw Story, 3 weeks ago
ABC News 4 Charleston, 3 weeks ago
Deccan Chronicle, 3 weeks ago
NEWS.com.au

Jerusalem clashes after school attack

The main clash site is at Qalandiya, between Jerusalem and Ramallah, though there are now reports of uprisings in the Old City portion of Jerusalem itself. #فلسطين 48 ألف متظاهر يسيرون من رام الله إلى القدس ...
 NEWS.com.au3 hours ago 10,000 Palestinians in protest clash  NEWS.com.au7 hours ago
[x]  

Human medicines European public assessment report (EPAR): Olanzapine Cipla (previously Olanzapine Neopharma), olanzapine, Revision: 12, Withdrawn

Product information 28/11/2013 Olanzapine Cipla (previously Olanzapine Neopharma) -EMEA/H/C/000793 -IB/14 Contents Annex I - Summary of product characteristics Annex IIA - Manufacturing-authorisation ...
 European Medicines Agency9 hours ago
MedPage Today

Update: Progress in Lupus Tx Slow But Sure (CME/CE)

Rheumatology Published: Jul 24, 2014 Reviewedby Zalman S. Agus, MD ; Emeritus Professor, Perelman School of Medicine at the University of Pennsylvania Progress toward improving the treatment of systemic lupus erythematosus (SLE) continues to be ...
 MedPage Today10 hours ago
Business Spectator

ANZ talks down sale urgency

ANZ Bank has moved to quell the urgency around it selling stakes in various Asian lenders to support the group's capital position and brushed off analysts scepticism of its newly released target for returns from institutional banking. Were not in ...
 Business Spectator11 hours ago

REG-Bank of New York Mellon FRN Variable Rate Fix

* Reuters is not responsible for the content in this press release. FRN Variable Rate Fix As Agent Bank, please be advised of the following rate determined on: 7/24/2014 Issue IIB Capital plc - Series 229180 EUR 95,000,000 FRN Due 27 Jan ...
 Reuters11 hours ago
Offshore Technology

Quasar 900 Gas Detector Certified for Ex Zone 1 Areas

The new SafEye Quasar 900 Series, with a range of models offering detection path lengths up to 200m, has been fully certified for use in Ex Zone 1 areas to ATEX, IECEx, FM and FMC standards. The Quasar 900's transmitter and receiver are each housed ...
 Offshore Technology12 hours ago
Aidsmap

New drug regimen speeds up TB treatment

MELBOURNE Dubbed the PaMZ regimen, the drugs killed more TB bacteria than standard therapy and at a faster rate in a so-called Phase IIb trial, usually the penultimate step in vetting new treatments for safety and effectiveness, investigators ...
 New Sabah Times2 days ago Novel TB regimen could reduce treatment duration  Aidsmap3 days ago Health: New drug regimen speeds TB treatment  Manila Bulletin12 hours ago Cocktail of Drugs Shortens Time Taken to Treat TB Patients  Med India3 days ago
[x]  
TeleTrader.com

Celgene Reports Second Quarter 2014 Operating and Financial Results

Celgene Corporation ( NASDAQ:CELG ) reported net product sales of $1,845 million for the second quarter of 2014, an 18 percent increase from the same period in 2013. Second quarter total revenue increased 17 percent to $1,873 ...
 Town Hall16 hours ago Half Yearly Report  MoneyAM1 day ago CELGENE : Reports Second Quarter 2014 Operating and Financial Results  4 Traders16 hours ago
[x]  
Consumer Electronics Net

DuPont Fabros Technology, Inc. Reports Second Quarter 2014 Results

Revenues increase 11%; Adjusted FFO per share increases 48%Midpoint of Normalized FFO guidance range increased $0.05 per share WASHINGTON, July 24, 2014 /PRNewswire/ -- DuPont Fabros Technology, Inc. (NYSE: DFT) is reporting results for the ...
 TickerTech.com17 hours ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less